Sunday - November 15, 2026
Bayer's asundexian first FXIa inhibitor approved by U.S. Food and Drug Administration for secondary stroke risk reduction
November 10, 2026
LEVERKUSEN, Germany, Nov. 10 [Category: BizPharmaceuticals] -- Bayer Group, a pharmaceutical and life sciences company, posted the following news release:

* * *

Bayer's asundexian first FXIa inhibitor approved by U.S. Food and Drug Administration for secondary stroke risk reduction

*

Berlin, November 10, 2026 - Bayer announced today that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for asundexian, 50 mg t . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products